DK2186902T3 - Medicinske præparater til behandling af alfa-galactosidase A-mangel - Google Patents

Medicinske præparater til behandling af alfa-galactosidase A-mangel

Info

Publication number: DK2186902T3
Authority: DK; Denmark
Prior art keywords: gal; methods; galactosidase; medications; deficiency
Prior art date: 1999-03-11

Application number

DK10152432.0T

Other languages

English (en)

Inventor

Richard Selden

Marianne Borowski

Carol M Kinoshita

Douglas A Treco

Melanie D Williams

Thomas J Schuetz

Peter Francis Daniel

Original Assignee

Shire Human Genetic Therapies

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-11

Filing date

2000-03-09

Publication date

2012-09-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23012821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2186902(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-03-09 Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies

2012-09-03 Application granted granted Critical

2012-09-03 Publication of DK2186902T3 publication Critical patent/DK2186902T3/da

Links

208000024720 Fabry Disease Diseases 0.000 title 1
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
238000002483 medication Methods 0.000 title 1
238000000034 method Methods 0.000 abstract 4
238000002360 preparation method Methods 0.000 abstract 4

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Diabetes (AREA)
Biophysics (AREA)
Toxicology (AREA)
Hematology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Immunology (AREA)
Physics & Mathematics (AREA)
Emergency Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)

DK10152432.0T 1999-03-11 2000-03-09 Medicinske præparater til behandling af alfa-galactosidase A-mangel DK2186902T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/266,014 US6458574B1 (en)	1996-09-12	1999-03-11	Treatment of a α-galactosidase a deficiency
EP06025159A EP1820862A3 (en)	1999-03-11	2000-03-09	Medical preparations for the treatment of alpha-galactosidase a deficiency

Publications (1)

Publication Number	Publication Date
DK2186902T3 true DK2186902T3 (da)	2012-09-03

Family

ID=23012821

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK10152432.0T DK2186902T3 (da)	1999-03-11	2000-03-09	Medicinske præparater til behandling af alfa-galactosidase A-mangel
DK10180768.3T DK2314699T3 (da)	1999-03-11	2000-03-09	Lægemiddelpræparater til behandlingen af alfa-galactosidase-a mangel
DK00913825T DK1163349T3 (da)	1999-03-11	2000-03-09	Medicinske præparater til behandling af alfa-galactosidase A-mangel

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DK10180768.3T DK2314699T3 (da)	1999-03-11	2000-03-09	Lægemiddelpræparater til behandlingen af alfa-galactosidase-a mangel
DK00913825T DK1163349T3 (da)	1999-03-11	2000-03-09	Medicinske præparater til behandling af alfa-galactosidase A-mangel

Country Status (22)

Country	Link
US (4)	US6458574B1 (da)
EP (6)	EP2314699B1 (da)
JP (6)	JP2002538183A (da)
KR (2)	KR100892334B1 (da)
CN (4)	CN100417727C (da)
AT (1)	ATE386808T1 (da)
AU (1)	AU3519400A (da)
CA (3)	CA2365923A1 (da)
CY (3)	CY1107951T1 (da)
DE (1)	DE60038104T2 (da)
DK (3)	DK2186902T3 (da)
ES (3)	ES2391221T3 (da)
HK (2)	HK1043386B (da)
HU (1)	HU228743B1 (da)
IL (2)	IL145381A0 (da)
MX (1)	MXPA01009222A (da)
NO (2)	NO329689B1 (da)
NZ (1)	NZ514077A (da)
PL (1)	PL210833B1 (da)
PT (3)	PT2186902E (da)
RU (1)	RU2248213C2 (da)
WO (1)	WO2000053730A2 (da)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6458574B1 (en) *	1996-09-12	2002-10-01	Transkaryotic Therapies, Inc.	Treatment of a α-galactosidase a deficiency
US6083725A (en) *	1996-09-13	2000-07-04	Transkaryotic Therapies, Inc.	Tranfected human cells expressing human α-galactosidase A protein
US20050032211A1 (en) *	1996-09-26	2005-02-10	Metabogal Ltd.	Cell/tissue culturing device, system and method
IL155588A0 (en) *	2003-04-27	2003-11-23	Metabogal Ltd	Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US20040005309A1 (en) *	2002-05-29	2004-01-08	Symbiontics, Inc.	Targeted therapeutic proteins
US7629309B2 (en)	2002-05-29	2009-12-08	Zystor Therapeutics, Inc.	Targeted therapeutic proteins
US7560424B2 (en)	2001-04-30	2009-07-14	Zystor Therapeutics, Inc.	Targeted therapeutic proteins
EP1436316B1 (en) *	2001-04-30	2008-01-23	ZyStor Therapeutics , Inc.	Subcellular targeting of therapeutic proteins
US20030072761A1 (en)	2001-10-16	2003-04-17	Lebowitz Jonathan	Methods and compositions for targeting proteins across the blood brain barrier
DK1503788T3 (da) *	2002-04-25	2011-10-17	Shire Human Genetic Therapies	Behandling af alpha-galactosidase A-deficiens
JP5589165B2 (ja) *	2003-01-31	2014-09-17	マウントシナイスクールオブメディシンオブニューヨークユニバーシティー	タンパク質欠損性障害の治療のための併用療法
US7422310B2 (en) *	2003-04-25	2008-09-09	Hewlett-Packard Development Company, L.P.	Methods and apparatus for selecting image enhancement techniques
US20100196345A1 (en) *	2003-04-27	2010-08-05	Protalix	Production of high mannose proteins in plant culture
US7951557B2 (en) *	2003-04-27	2011-05-31	Protalix Ltd.	Human lysosomal proteins from plant cell culture
US7442372B2 (en) †	2003-08-29	2008-10-28	Biomarin Pharmaceutical Inc.	Delivery of therapeutic compounds to the brain and other tissues
DE602005020745D1 (de)	2004-02-10	2010-06-02	Zystor Therapeutics Inc	Saure alpha-glukosidase und fragmente davon
US20050208090A1 (en) *	2004-03-18	2005-09-22	Medtronic, Inc.	Methods and systems for treatment of neurological diseases of the central nervous system
EP1773401B1 (en) *	2004-06-21	2013-01-02	Medtronic, Inc.	Medical systems and methods for delivering compositions to cells
CN1308444C (zh) *	2005-04-15	2007-04-04	中国人民解放军军事医学科学院野战输血研究所	基因重组α－半乳糖苷酶大批量发酵液的纯化方法
EP3782655A1 (en)	2005-05-17	2021-02-24	Amicus Therapeutics, Inc.	A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
JP4368925B2 (ja) *	2005-11-18	2009-11-18	財団法人東京都医学研究機構	基質特異性を変換した新規高機能酵素
WO2007086067A1 (en) *	2006-01-30	2007-08-02	Diagnostic Technologies Ltd.	Method for monitoring tocolytic treatment
AU2007322123A1 (en) *	2006-11-13	2008-05-29	Biomarin Pharmaceutical Inc.	Methods for treating Pompe disease
ES2660667T3 (es) *	2007-05-07	2018-03-23	Protalix Ltd.	Biorreactor desechable a gran escala
US20100291060A1 (en) *	2007-08-29	2010-11-18	Shire Human Genetic Therapies, Inc	Subcutaneous administration of alpha-galactosidase a
WO2009137721A2 (en)	2008-05-07	2009-11-12	Zystor Therapeutics, Inc.	Lysosomal targeting peptides and uses thereof
US9050276B2 (en)	2009-06-16	2015-06-09	The Trustees Of Columbia University In The City Of New York	Autism-associated biomarkers and uses thereof
US8785168B2 (en)	2009-06-17	2014-07-22	Biomarin Pharmaceutical Inc.	Formulations for lysosomal enzymes
US9194011B2 (en)	2009-11-17	2015-11-24	Protalix Ltd.	Stabilized alpha-galactosidase and uses thereof
DK2865751T3 (da) *	2010-03-02	2017-01-09	Protalix Ltd	Stabiliseret alpha-galactosidase og anvendelser deraf
US20110293585A1 (en) *	2010-04-21	2011-12-01	Helix Therapeutics, Inc.	Compositions and methods for treatment of lysosomal storage disorders
EA202090067A3 (ru) *	2010-07-08	2020-07-31	Баксалта Инкорпорейтид	Способ получения рекомбинантного adamts13 в культуре клеток
CN103391784A (zh)	2010-10-15	2013-11-13	纽约市哥伦比亚大学理事会	肥胖症-相关的基因和它们的蛋白和其用途
PT2635299T (pt)	2010-11-02	2019-10-14	Univ Columbia	Métodos de tratamento de distúrbios de perda de cabelo
JP5975577B2 (ja)	2011-03-04	2016-08-23	株式会社糖鎖工学研究所	シアル酸含有糖鎖の製造方法
KR20220025112A (ko)	2011-06-08	2022-03-03	샤이어 휴먼 지네틱 테라피즈 인크.	Mrna 전달을 위한 지질 나노입자 조성물 및 방법
KR20200032244A (ko)	2012-03-07	2020-03-25	아미쿠스 세라퓨틱스, 인코포레이티드	폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
US10039777B2 (en)	2012-03-20	2018-08-07	Neuro-Lm Sas	Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
DK2830662T3 (da)	2012-03-29	2019-01-02	Univ Columbia	Fremgangsmåder til behandlng af hårtabsforstyrrelser
EP2874648A4 (en)	2012-07-17	2015-12-30	Amicus Therapeutics Inc	ALPHA GALACTOSIDASE A AND 1-DEOXYGALACTONO JIRIMYCIN CO FORMULATION
US10155027B2 (en)	2012-07-17	2018-12-18	Amicus Therapeutics, Inc.	Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
WO2014016873A1 (en)	2012-07-26	2014-01-30	Jcr Pharmaceuticals Co., Ltd.	Method for production of recombinant human alpha-galactosidase a
WO2014120900A1 (en) *	2013-01-31	2014-08-07	Icahn School Of Medicine At Mount Sinai	Enhanced therapeutic regimens for treating fabry disease
EA201591283A1 (ru)	2013-03-14	2016-02-29	Шир Хьюман Дженетик Терапис, Инк.	Количественная оценка эффективности кэп матричной рнк
MX2015011945A (es)	2013-03-14	2015-12-01	Shire Human Genetic Therapies	Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero.
TWI793159B (zh)	2013-10-23	2023-02-21	美商健臻公司	重組醣蛋白及其用途
US9682123B2 (en)	2013-12-20	2017-06-20	The Trustees Of Columbia University In The City Of New York	Methods of treating metabolic disease
MX368972B (es) *	2014-03-05	2019-10-23	Ultragenyx Pharmaceutical Inc	Composiciones de glicoproteínas sialiladas y usos de estas.
JP6851964B2 (ja)	2014-09-30	2021-03-31	アミカスセラピューティックスインコーポレイテッド	炭水化物が増大している非常に強力な酸性アルファ−グルコシダーゼ
CA2970638A1 (en)	2014-12-22	2016-06-30	Codexis, Inc.	Human alpha-galactosidase variants
KR102769649B1 (ko)	2014-12-22	2025-02-19	젠자임 코포레이션	포유류 세포의 배양 방법
WO2016116966A1 (en)	2015-01-22	2016-07-28	Jcr Pharmaceuticals Co., Ltd.	Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
US9981021B1 (en)	2015-04-09	2018-05-29	Kinetiq, Inc.	Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
GB201508025D0 (en)	2015-05-11	2015-06-24	Ucl Business Plc	Fabry disease gene therapy
EP3347486A4 (en)	2015-09-09	2019-06-19	The Trustees of Columbia University in the City of New York	REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
IL299470B2 (en)	2015-12-30	2026-05-01	Amicus Therapeutics Inc	Improved acid alpha-glucosidase for the treatment of Pompe disease
JP2019508037A (ja)	2016-02-16	2019-03-28	イェールユニバーシティーＹａｌｅＵｎｉｖｅｒｓｉｔ	標的化遺伝子編集を増強するための組成物およびその使用方法
CA3019354A1 (en)	2016-03-30	2017-10-05	Amicus Therapeutics, Inc.	Method for selection of high m6p recombinant proteins
KR102618519B1 (ko)	2016-03-30	2023-12-28	아미쿠스 세라퓨틱스, 인코포레이티드	재조합 산 알파-글루코시다제를 포함하는 제형
NL2017294B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Natural cryptic exon removal by pairs of antisense oligonucleotides.
WO2018071814A1 (en)	2016-10-14	2018-04-19	The Trustees Of Columbia University In The City Of New York	Methods of treating alcohol abuse disorder
KR102712926B1 (ko) *	2016-10-20	2024-10-07	상가모 테라퓨틱스, 인코포레이티드	파브리병의 치료를 위한 방법 및 조성물
US11357834B2 (en)	2017-01-10	2022-06-14	Amicus Therapeutics, Inc.	Recombinant α-galactosidase A for treatment of Fabry disease
EA039750B1 (ru) *	2017-03-30	2022-03-10	Амикус Терапьютикс, Инк.	Способ отбора рекомбинантных белков с высоким содержанием m6p
WO2018187493A1 (en)	2017-04-04	2018-10-11	Yale University	Compositions and methods for in utero delivery
CN119113091A (zh)	2017-05-15	2024-12-13	阿米库斯治疗学公司	重组人类酸性α-葡萄糖苷酶
US11708569B2 (en) *	2018-08-29	2023-07-25	University Of Copenhagen	Modified recombinant lysosomal alpha-galactosidase A and aspartylglucoaminidase having low mannose-6-phosphate and high sialic acid
MY207075A (en) *	2018-12-20	2025-01-28	Codexis Inc	Human alpha-galactosidase variants
CN113423419A (zh)	2019-01-04	2021-09-21	桑格摩生物治疗股份有限公司	用于治疗法布里病的方法和组合物
EP3996696A1 (en)	2019-07-09	2022-05-18	Genethon	Treatment of glycogen storage disease (gsd)
TW202128264A (zh)	2019-09-25	2021-08-01	瑞士商赫孚孟拉羅股份公司	使用經預測之溶離緩衝鹽濃度的陽離子層析法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5322158B2 (da) *	1974-05-02	1978-07-06
US4407957A (en)	1981-03-13	1983-10-04	Damon Corporation	Reversible microencapsulation of a core material
US4740365A (en)	1984-04-09	1988-04-26	Toyo Boseki Kabushiki Kaisha	Sustained-release preparation applicable to mucous membrane in oral cavity
US4764376A (en)	1984-06-18	1988-08-16	Eli Lilly And Company	Method of inhibiting aromatase
GB8530631D0 (en) *	1985-12-12	1986-01-22	Ciba Geigy Ag	Thrombin inhibitors
US4764378A (en)	1986-02-10	1988-08-16	Zetachron, Inc.	Buccal drug dosage form
US5272066A (en) *	1986-03-07	1993-12-21	Massachusetts Institute Of Technology	Synthetic method for enhancing glycoprotein stability
EP0463109A4 (en)	1989-03-24	1992-11-19	Research Corporation Technologies, Inc.	Recombinant alpha-galactosidase, a therapy for fabry disease
US5179023A (en) *	1989-03-24	1993-01-12	Research Corporation Technologies, Inc.	Recombinant α-galactosidase a therapy for Fabry disease
KR0159107B1 (ko) *	1989-07-13	1998-11-16	쟝 르쌍드뢰	우레이트 산화효소 활성 단백질, 이 단백질을 암호화하는 재조합 유전자, 발현 벡터, 미생물 및 형질전환세포
EP0446315B1 (en) *	1989-09-05	1997-06-11	Biotechnology Australia Pty. Ltd.	Process for the preparation of pai-2
US5661132A (en) *	1989-12-14	1997-08-26	Auragen, Inc.	Wound healing
US5697901A (en) *	1989-12-14	1997-12-16	Elof Eriksson	Gene delivery by microneedle injection
US5356804A (en)	1990-10-24	1994-10-18	Mount Sinai School Of Medicine Of The City Of New York	Cloning and expression of biologically active human α-galactosidase A
US5401650A (en) *	1990-10-24	1995-03-28	The Mount Sinai School Of Medicine Of The City University Of New York	Cloning and expression of biologically active α-galactosidase A
SG47470A1 (en)	1991-04-25	1998-04-17	Univ Brown Res Found	Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products
ES2141108T3 (es)	1991-07-02	2000-03-16	Inhale Inc	Metodo y dispositivo para proporcionar medicamentos en aerosol.
US5750376A (en)	1991-07-08	1998-05-12	Neurospheres Holdings Ltd.	In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
NZ245015A (en)	1991-11-05	1995-12-21	Transkaryotic Therapies Inc	Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US5968502A (en)	1991-11-05	1999-10-19	Transkaryotic Therapies, Inc.	Protein production and protein delivery
US5858751A (en)	1992-03-09	1999-01-12	The Regents Of The University Of California	Compositions and methods for producing sialyltransferases
ATE155681T1 (de)	1992-05-18	1997-08-15	Minnesota Mining & Mfg	Einrichtung zur transmucosalen wirkstoffabgabe
US5785049A (en)	1994-09-21	1998-07-28	Inhale Therapeutic Systems	Method and apparatus for dispersion of dry powder medicaments
US5383851A (en)	1992-07-24	1995-01-24	Bioject Inc.	Needleless hypodermic injection device
US5804413A (en)	1992-07-31	1998-09-08	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Herpes simplex virus strains for gene transfer
US5569189A (en)	1992-09-28	1996-10-29	Equidyne Systems, Inc.	hypodermic jet injector
DK0679088T3 (da)	1992-09-29	2002-10-28	Inhale Therapeutic Syst	Pulmonal levering af aktive fragmenter af parathyreoideaea hormon
US5389539A (en)	1992-11-30	1995-02-14	Massachusetts Institute Of Technology	Purification of heparinase I, II, and III from Flavobacterium heparinum
US6329191B1 (en)	1993-08-30	2001-12-11	Hawaii Biotechnology Group, Inc.	DNA encoding recombinant coffee bean alpha-galactosidase
US5770405A (en) *	1993-09-23	1998-06-23	New England Biolabs, Inc.	Isolation and composition of novel glycosidases
DE4339605A1 (de)	1993-11-20	1995-05-24	Beiersdorf Ag	Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Fettsäurepartialglyceriden
US5843015A (en)	1993-12-28	1998-12-01	Becton Dickinson And Company	Molecules for iontophoretic delivery
US5789247A (en)	1994-04-01	1998-08-04	Ballay; Annick	Expression in non-tumoral human lymphoblastoid lines with an integrative vector
FR2718357B1 (fr)	1994-04-06	1997-10-03	Defarges Alain Moreau	Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5834251A (en) *	1994-12-30	1998-11-10	Alko Group Ltd.	Methods of modifying carbohydrate moieties
US5599302A (en)	1995-01-09	1997-02-04	Medi-Ject Corporation	Medical injection system and method, gas spring thereof and launching device using gas spring
EP0807165A4 (en) *	1995-01-30	1998-07-15	New York Blood Center Inc	RECOMBINANT -g (a) -GALACTOSIDASE ENZYME
US5780014A (en)	1995-04-14	1998-07-14	Inhale Therapeutic Systems	Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en)	1995-06-07	1997-08-05	Inhale Therapeutic Systems	Methods and system for processing dispersible fine powders
US6566089B1 (en) *	1996-09-04	2003-05-20	Tularik Inc.	Cell-based drug screens for regulators of gene expression
US6458574B1 (en) *	1996-09-12	2002-10-01	Transkaryotic Therapies, Inc.	Treatment of a α-galactosidase a deficiency
NZ506214A (en)	1996-09-13	2002-11-26	Transkaryotic Therapies Inc	Therapy for alpha-galactosidase A deficiency
US6083725A (en) *	1996-09-13	2000-07-04	Transkaryotic Therapies, Inc.	Tranfected human cells expressing human α-galactosidase A protein
IL125423A (en) *	1998-07-20	2004-08-31	Israel State	Alkaline alpha-galactosidase having broad substrate specificity
US6749851B2 (en) *	2001-08-31	2004-06-15	Clearant, Inc.	Methods for sterilizing preparations of digestive enzymes

1999
- 1999-03-11 US US09/266,014 patent/US6458574B1/en not_active Expired - Lifetime
2000
- 2000-03-09 JP JP2000603353A patent/JP2002538183A/ja active Pending
- 2000-03-09 ES ES10152432T patent/ES2391221T3/es not_active Expired - Lifetime
- 2000-03-09 EP EP10180768.3A patent/EP2314699B1/en not_active Expired - Lifetime
- 2000-03-09 CA CA002365923A patent/CA2365923A1/en active Pending
- 2000-03-09 DK DK10152432.0T patent/DK2186902T3/da active
- 2000-03-09 RU RU2001127533/15A patent/RU2248213C2/ru active
- 2000-03-09 EP EP17169335.1A patent/EP3231871A1/en not_active Withdrawn
- 2000-03-09 HK HK02104366.6A patent/HK1043386B/en not_active IP Right Cessation
- 2000-03-09 DK DK10180768.3T patent/DK2314699T3/da active
- 2000-03-09 CN CNB008073120A patent/CN100417727C/zh not_active Expired - Lifetime
- 2000-03-09 HU HU0200467A patent/HU228743B1/hu unknown
- 2000-03-09 AT AT00913825T patent/ATE386808T1/de active
- 2000-03-09 CA CA2833396A patent/CA2833396C/en not_active Expired - Lifetime
- 2000-03-09 PT PT10152432T patent/PT2186902E/pt unknown
- 2000-03-09 NZ NZ514077A patent/NZ514077A/xx not_active IP Right Cessation
- 2000-03-09 KR KR1020017011552A patent/KR100892334B1/ko not_active Expired - Lifetime
- 2000-03-09 PT PT00913825T patent/PT1163349E/pt unknown
- 2000-03-09 KR KR1020077019031A patent/KR100961740B1/ko not_active Expired - Lifetime
- 2000-03-09 AU AU35194/00A patent/AU3519400A/en not_active Abandoned
- 2000-03-09 EP EP00913825A patent/EP1163349B1/en not_active Expired - Lifetime
- 2000-03-09 WO PCT/US2000/006118 patent/WO2000053730A2/en not_active Ceased
- 2000-03-09 DE DE60038104T patent/DE60038104T2/de not_active Expired - Lifetime
- 2000-03-09 MX MXPA01009222A patent/MXPA01009222A/es active IP Right Grant
- 2000-03-09 CN CN201310243356.3A patent/CN103585621B/zh not_active Expired - Lifetime
- 2000-03-09 EP EP10180757A patent/EP2287319A1/en not_active Withdrawn
- 2000-03-09 CA CA3012663A patent/CA3012663A1/en not_active Expired - Lifetime
- 2000-03-09 IL IL14538100A patent/IL145381A0/xx unknown
- 2000-03-09 EP EP10152432A patent/EP2186902B1/en not_active Revoked
- 2000-03-09 CN CNA2007101482923A patent/CN101219213A/zh not_active Withdrawn
- 2000-03-09 CN CN201610478912.9A patent/CN106110309A/zh active Pending
- 2000-03-09 ES ES00913825T patent/ES2300256T3/es not_active Expired - Lifetime
- 2000-03-09 PT PT101807683T patent/PT2314699T/pt unknown
- 2000-03-09 EP EP06025159A patent/EP1820862A3/en not_active Ceased
- 2000-03-09 PL PL350658A patent/PL210833B1/pl unknown
- 2000-03-09 ES ES10180768.3T patent/ES2634317T3/es not_active Expired - Lifetime
- 2000-03-09 DK DK00913825T patent/DK1163349T3/da active
2001
- 2001-09-11 NO NO20014415A patent/NO329689B1/no not_active IP Right Cessation
- 2001-09-11 IL IL145381A patent/IL145381A/en not_active IP Right Cessation
2002
- 2002-06-07 US US10/165,060 patent/US20030077806A1/en not_active Abandoned
- 2002-06-10 US US10/165,968 patent/US20030113894A1/en not_active Abandoned
2008
- 2008-05-20 CY CY20081100521T patent/CY1107951T1/el unknown
2010
- 2010-09-27 JP JP2010215000A patent/JP5615648B2/ja not_active Expired - Lifetime
- 2010-10-22 NO NO20101493A patent/NO20101493L/no not_active Application Discontinuation
- 2010-11-11 US US12/944,688 patent/US20110280856A1/en not_active Abandoned
2012
- 2012-08-10 CY CY20121100736T patent/CY1113051T1/el unknown
2013
- 2013-08-26 JP JP2013174418A patent/JP5899169B2/ja not_active Expired - Lifetime
2014
- 2014-12-16 JP JP2014254079A patent/JP6081980B2/ja not_active Expired - Lifetime
2016
- 2016-10-12 JP JP2016200833A patent/JP6346236B2/ja not_active Expired - Lifetime
2017
- 2017-07-26 CY CY20171100801T patent/CY1119369T1/el unknown
- 2017-11-15 JP JP2017219734A patent/JP6626071B2/ja not_active Expired - Lifetime
2018
- 2018-04-03 HK HK18104453.2A patent/HK1245320A1/en unknown

Also Published As

Publication number	Publication date
CN106110309A (zh)	2016-11-16
JP2018038423A (ja)	2018-03-15
EP2287319A1 (en)	2011-02-23
PT2186902E (pt)	2012-08-28
HK1043386B (en)	2008-06-13
PL350658A1 (en)	2003-01-27
CY1107951T1 (el)	2013-09-04
ATE386808T1 (de)	2008-03-15
DK2314699T3 (da)	2017-08-07
AU3519400A (en)	2000-09-28
EP2186902B1 (en)	2012-05-23
CN103585621B (zh)	2016-08-10
KR100892334B1 (ko)	2009-04-08
DE60038104D1 (de)	2008-04-03
PT2314699T (pt)	2017-08-01
CA2833396C (en)	2018-08-28
JP6346236B2 (ja)	2018-06-20
EP2186902A2 (en)	2010-05-19
US20030113894A1 (en)	2003-06-19
IL145381A0 (en)	2002-06-30
JP5899169B2 (ja)	2016-04-06
US20110280856A1 (en)	2011-11-17
PL210833B1 (pl)	2012-03-30
JP5615648B2 (ja)	2014-10-29
ES2391221T3 (es)	2012-11-22
EP2186902A3 (en)	2010-09-01
NZ514077A (en)	2004-02-27
JP2015091834A (ja)	2015-05-14
EP1820862A3 (en)	2007-10-31
MXPA01009222A (es)	2002-06-04
CY1119369T1 (el)	2018-02-14
EP1163349A2 (en)	2001-12-19
EP1820862A2 (en)	2007-08-22
ES2300256T3 (es)	2008-06-16
US20030077806A1 (en)	2003-04-24
CA2365923A1 (en)	2000-09-14
NO20014415D0 (no)	2001-09-11
CY1113051T1 (el)	2016-04-13
NO20014415L (no)	2001-11-12
RU2248213C2 (ru)	2005-03-20
HU228743B1 (en)	2013-05-28
KR20070090277A (ko)	2007-09-05
NO329689B1 (no)	2010-11-29
DE60038104T2 (de)	2009-02-12
HK1245320A1 (en)	2018-08-24
JP2017014279A (ja)	2017-01-19
CN1354796A (zh)	2002-06-19
KR100961740B1 (ko)	2010-06-07
IL145381A (en)	2009-12-24
HK1143833A1 (en)	2011-01-14
JP2002538183A (ja)	2002-11-12
US6458574B1 (en)	2002-10-01
WO2000053730A3 (en)	2001-03-15
CN100417727C (zh)	2008-09-10
EP2314699A1 (en)	2011-04-27
JP2013241466A (ja)	2013-12-05
PT1163349E (pt)	2008-05-19
DK1163349T3 (da)	2008-06-23
CA2833396A1 (en)	2000-09-14
HUP0200467A3 (en)	2006-06-28
EP2314699B1 (en)	2017-05-31
CN103585621A (zh)	2014-02-19
KR20020021371A (ko)	2002-03-20
CN101219213A (zh)	2008-07-16
JP6626071B2 (ja)	2019-12-25
EP1163349B1 (en)	2008-02-20
ES2634317T3 (es)	2017-09-27
WO2000053730A9 (en)	2001-10-11
JP2011037867A (ja)	2011-02-24
WO2000053730A2 (en)	2000-09-14
CA3012663A1 (en)	2000-09-14
JP6081980B2 (ja)	2017-02-15
HK1043386A1 (en)	2002-09-13
HUP0200467A2 (en)	2002-06-29
NO20101493L (no)	2001-11-12
EP3231871A1 (en)	2017-10-18

Publication	Publication Date	Title
DK1163349T3 (da)	2008-06-23	Medicinske præparater til behandling af alfa-galactosidase A-mangel
DK1539166T3 (da)	2008-10-20	Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
TR199800012T1 (xx)	1998-04-21	Piroloprimidinler ve preparasyon i�in tatbikler.
CY1108706T1 (el)	2014-04-09	Ανοσορυθμιστης
NO971889L (no)	1997-06-23	Forbindelser og sammensetninger for levering av aktive midler
BR9806752A (pt)	2000-03-14	Ftalazinonas.
NO873298L (no)	1988-02-08	Oralt terapeutisk system med systematisk virkning.
DK0973735T3 (da)	2003-06-23	Polyaromatiske antivirale præparater
DK1003546T3 (da)	2006-10-30	Fremgangsmåde til behandling af patienter ramt af dissemineret sklerose ved anvendelse af konsensus interferon
TR199901949T2 (xx)	2000-01-21	Lemfositik t�m�rler i�in �areler.
DK0725637T3 (da)	2001-03-26	Parenteralt busulfan til behandling af malign sygdom
NO972391D0 (no)	1997-05-26	2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
ATE249835T1 (de)	2003-10-15	Immunoregulator
EA199900633A1 (ru)	2000-02-28	Способы терапевтического введения анти-cd40l соединений
ATE188873T1 (de)	2000-02-15	Tris-platin-komplexe
TR200001486T2 (tr)	2001-07-23	Hiperkeratozlu deri hastalıklarının tedavisi için diol ve alfa-hidroksi asitten oluşan bir karışımın kullanılması
AU8239298A (en)	1999-02-08	Nucleotide-comprising composition
TR200001102T2 (tr)	2000-08-21	İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
DE60222383D1 (de)	2007-10-25	Medikament zur verabreichung von amifostin und verwandten wirkstoffen
DE69414194D1 (de)	1998-12-03	Aminosäurederivate und ihre Verwendung als Enkephalinase-Inhibitoren
NO20020914L (no)	2002-04-26	Alkoksy-substituerte benzimidazolforbindelser, preparater inneholdende slike samt anvendelser derav
ATE356144T1 (de)	2007-03-15	Regulatorische/entfaltende peptide von ezrin
EA200000163A1 (ru)	2000-10-30	Противоопухолевое средство
BR9812002A (pt)	2000-09-26	Compostos com efeito antiprimeiro-passe
IT8720800A0 (it)	1987-06-05	Composto attivo nella terapia carciovascolare.